SCHEMBL7008320

SCHEMBL7008320

CCOC(=O)n1cc(-n2c(-c3c[nH]c4ccccc34)c[nH]c2=O)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.41
PRKACA P17612 6/20 0.41
PRKACG P22612 6/20 0.41
PRKACB P22694 6/20 0.41
PKM P14618 2/20 0.41
KMT2A Q03164 3/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CDK4 P11802 3/20 0.40
CCND1 P24385 3/20 0.40
CAMK2D Q13557 2/20 0.40
CCNT1 O60563 2/20 0.39
CDK9 P50750 2/20 0.39
PIM1 P11309 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7003853 0.89 CAMK2D (0.42) KMT2AGAAMEN1ALDH1A1CAMK2D
SCHEMBL7006065 0.86 PKM (0.39) RPS6KB1PRKACAPRKACGPRKACBPKM
SCHEMBL7008865 0.86 PIM1 (0.40) CDK4CCND1CAMK2DCCNT1CDK9
SCHEMBL7009411 0.80 ALDH1A1 (0.41) RPS6KB1PRKACAPRKACGPRKACBKMT2A
SCHEMBL7010209 0.76 PIM1 (0.37) RPS6KB1PRKACAPRKACGPRKACBKMT2A
SCHEMBL7010672 0.74 SIRT2 (0.48) PRKACAPRKACGPRKACBKMT2AMEN1
SCHEMBL7004515 0.70 SIRT2 (0.43) PRKACAPRKACGPRKACBKMT2AGAA
SCHEMBL7005539 0.69 CDK4 (0.55) RPS6KB1PRKACAPRKACGPRKACBKMT2A
SCHEMBL8159852 0.67 ALDH1A1 (0.46) KMT2AGAAMEN1ALDH1A1CCNT1
SCHEMBL2114760 0.67 L3MBTL1 (0.54) KMT2AMEN1ALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134886-A1 Pharmaceutically active compounds ASTRAZENECA AB, A SWEDISH CORPORATION 2003-07-17 US disclosed
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-6492409-B1 SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-10 US disclosed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134886-A1 Pharmaceutically active compounds HTR3C, HTR6, CNR1 RPS6KB1 593/4885PRKACA 3300/4885PRKACG 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.